• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    10/24/23 5:31:31 PM ET
    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACRX alert in real time by email

    Gainers

    • Reshape Lifesciences (NASDAQ:RSLS) stock rose 30.2% to $0.27 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 1.8 million shares, which is 104.8 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $1.3 million.
    • Cognition Therapeutics (NASDAQ:CGTX) shares rose 11.57% to $1.35. The market value of their outstanding shares is at $40.9 million.
    • GRI Bio (NASDAQ:GRI) shares increased by 10.08% to $1.2. The company's market cap stands at $3.5 million.
    • Vicarious Surgical (NYSE:RBOT) shares moved upwards by 10.06% to $0.41. The company's market cap stands at $70.6 million.
    • AcelRx Pharmaceuticals (NASDAQ:ACRX) shares increased by 9.8% to $0.56. The market value of their outstanding shares is at $9.1 million.
    • AlloVir (NASDAQ:ALVR) shares increased by 9.15% to $1.55. The company's market cap stands at $176.4 million.

    Losers

    • Tharimmune (NASDAQ:THAR) shares declined by 20.6% to $0.2 during Tuesday's after-market session. This security traded at a volume of 559.5K shares come close, making up 35.3% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.5 million.
    • Biocept (NASDAQ:BIOC) shares declined by 17.27% to $0.36. Today's trading volume for this security ended up closing at 129.0K shares, which is 6.1 percent of its average volume over the last 100 days.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares fell 13.26% to $1.57. The market value of their outstanding shares is at $2.7 million.
    • Motus GI Hldgs (NASDAQ:MOTS) shares fell 11.37% to $0.59. Motus GI Hldgs's trading volume hit 1.6 million shares by close, accounting for 1949.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.4 million.
    • IO Biotech (NASDAQ:IOBT) stock decreased by 9.35% to $0.97. The company's market cap stands at $63.9 million.
    • Titan Pharma (NASDAQ:TTNP) shares fell 9.16% to $0.35. The company's market cap stands at $5.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRX
    $ALVR
    $BIOC
    $CGTX

    CompanyDatePrice TargetRatingAnalyst
    IO Biotech Inc.
    $IOBT
    1/26/2026$0.50Overweight → Neutral
    Piper Sandler
    IO Biotech Inc.
    $IOBT
    1/8/2026$0.36Equal-Weight → Underweight
    Morgan Stanley
    IO Biotech Inc.
    $IOBT
    9/30/2025$0.39Overweight → Equal-Weight
    Morgan Stanley
    IO Biotech Inc.
    $IOBT
    9/30/2025Buy → Hold
    TD Cowen
    Cognition Therapeutics Inc.
    $CGTX
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    GRI Bio Inc.
    $GRI
    12/9/2024$10.00Buy
    H.C. Wainwright
    Cognition Therapeutics Inc.
    $CGTX
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    AlloVir Inc.
    $ALVR
    12/26/2023$17.00 → $1.00Buy → Underperform
    BofA Securities
    More analyst ratings

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    IO Biotech downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded IO Biotech from Overweight to Neutral and set a new price target of $0.50

    1/26/26 10:01:23 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded IO Biotech from Equal-Weight to Underweight and set a new price target of $0.36

    1/8/26 8:40:06 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IO Biotech downgraded by TD Cowen

    TD Cowen downgraded IO Biotech from Buy to Hold

    9/30/25 8:32:59 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Appajosyula Sireesh bought $90,973 worth of shares (61,496 units at $1.48), increasing direct ownership by 1,824% to 64,868 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:31:11 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cognition Therapeutics CEO Issues Letter to Shareholders

    Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER To my fellow Shareholders, We made significant progress in 2025 towards our goal of developing transformative treatments for neurodegenerative diseases. As discussed on our

    3/31/26 4:30:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair

    WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc

    3/30/26 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    SEC Filings

    View All

    IO Biotech Inc. filed SEC Form 8-K: Bankruptcy or Receivership

    8-K - IO Biotech, Inc. (0001865494) (Filer)

    3/31/26 8:00:07 AM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Cognition Therapeutics Inc.

    S-8 - COGNITION THERAPEUTICS INC (0001455365) (Filer)

    3/26/26 7:53:02 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Cognition Therapeutics Inc.

    10-K - COGNITION THERAPEUTICS INC (0001455365) (Filer)

    3/26/26 7:40:32 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Sachs Adam David sold $1,967 worth of shares (942 units at $2.09), decreasing direct ownership by 2% to 46,943 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:59:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    Chief Technology Officer Khalifa Sammy sold $1,571 worth of shares (754 units at $2.08), decreasing direct ownership by 2% to 32,869 units (SEC Form 4)

    4 - Vicarious Surgical Inc. (0001812173) (Issuer)

    2/24/26 4:58:35 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    CEO & President Ricciardi Lisa covered exercise/tax liability with 5,850 shares, decreasing direct ownership by 0.34% to 1,706,676 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    2/18/26 4:17:18 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

    Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toomey Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced the appointment of seasoned financial executive Jacob Asbury as Chief Financial Officer, effective immediately. In this role, he will oversee all financial strategy and operations, including capital planning, treasury management, financial reporting, and the continued expansion of Tharimmune's CC treasury infrastructure. Mr. Asbury brings nearly two d

    12/12/25 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.

    SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)

    11/14/24 4:22:34 PM ET
    $MOTS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by IO Biotech Inc.

    SC 13G/A - IO Biotech, Inc. (0001865494) (Subject)

    11/13/24 5:30:28 PM ET
    $IOBT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AlloVir Inc.

    SC 13G - Allovir, Inc. (0001754068) (Subject)

    10/11/24 4:02:13 PM ET
    $ALVR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRX
    $ALVR
    $BIOC
    $CGTX
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics CEO Issues Letter to Shareholders

    Advancing Zervimesine (CT1812) towards late-stage trials for dementia with Lewy bodies (DLB) psychosis Fully funded $80 million Phase 2 START trial readout expected in the second half of 2027 PURCHASE, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders, has published CEO Lisa Ricciardi's Letter to Shareholders. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER To my fellow Shareholders, We made significant progress in 2025 towards our goal of developing transformative treatments for neurodegenerative diseases. As discussed on our

    3/31/26 4:30:00 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

    PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.    Conference Call InformationTo participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webc

    3/23/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care